Medicure Inc. (MPH) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Medicare's Earnings Conference Call for the quarter ended March 31st, 2026. My name is Holly and I will be your operator for today's call. At this time, all participants are in listen-only mode. Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events, and expectations which are made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F. Later, we will conduct a question and answer session. Please note that this conference call is being recorded, and today's date is May 25, 2026. I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of MediCure, Inc. Please go ahead, Dr. Friesen. Thank you, Holly, and good morning to all on the call. We appreciate your interest and participation in today's call. Joining me today on the Q1 2026 conference call is Haris Uddin, Medicare's Chief Financial Officer. Net revenue for the quarter was $7.9 million compared to $5.5 million for the quarter ending March 31st, 2025. The company recorded a net loss for the quarter of $406,000 or $0.04 per share compared to a net loss of $694,000, or $0.07 a share, on the March 31, 2025 quarter. The net loss is due to non-cash expenses, including $644,000 of amortization on the assets related to the purchase of Zyphidimed and the pharmacy business, and $855,000 invested in the R&D, primarily the MC1 f...